Reuters
14 Aug 2026, 10:39 UTC · 1h ago
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
14 Aug 2026, 10:39 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The FDA is willing to review new data regarding Capricor Therapeutics' experimental Duchenne muscular dystrophy drug. — FDA openness to new data significantly increases the probability of regulatory approval for a high-need therapeutic.
+0.80Capricor Therapeutics shares more than doubled in premarket trading following the FDA news. — Strong immediate market validation of the news, though this is a reaction to the primary catalyst rather than a new fundamental driver.
+0.30Which stocks this story touches
Shares doubled following news that the FDA is willing to review new data for its Duchenne muscular dystrophy drug.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
2h ago
